AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease. The placebo-controlled study enrolled 34 participants, with 25 receiving ACI-7104.056 and ni
AC Immune reported positive safety and immunogenicity results from Part 1 of its Phase 2 Parkinson's disease trial for ACI-7104.
All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizationsClear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below Lausanne, Switzerland, September 23, 2026 –
This is the newest page. Registered accounts read further back.